2019.02.21
source：Neurelis, Inc.SAN DIEGO, CA – February 20, 2019 – Neurelis, Inc. announced today that its Intravail® licensing partner, ARS Pharmaceuticals, Inc., received Fast Track
designation from the FDA for ARS-1, its novel intranasal epinephrine
spray. ARS-1 is being investigated as a treatment for patients with
severe allergic reactions to food, medications and insect bites that
could lead to life-threatening anaphylaxis.
Neurelis President and CEO Craig Chambliss stated, “This latest news
provides more validation of Intravail’s crucial role in the development
of innovative products targeting areas of high unmet needs. We
congratulate the ARS team on the tremendous progress of their ARS-1
treatment, which has the potential to offer people at risk for
life-threatening anaphylaxis, low-dose, safe, and convenient treatment.”
Chambliss said the science of Intravail enables the non-invasive delivery of a broad range of protein, peptide and small molecule drugs, providing several advantages:
Increased bioavailability – Addressing sub-optimal bioavailability or route-of-administrations
Application to wide range of molecules – Small molecules, therapeutic proteins, peptides, non-peptide macromolecules (up to ~ 30KDa)
Safety – Odorless, tasteless, non-toxic, non-mutagenic and non-irritating
Solubility in water/oils – Compatible with routine liquid formulation and dispensing processes for ease of scale-up and production
Neurelis’ pipeline utilizes Intravail to develop novel
formulations of drugs targeting areas of significant unmet medical needs
in central nervous system (CNS) diseases. Neurelis is also fortunate to
partner Intravail with a number of licensees furthering the development
of important drugs in a variety of diseases - continuing to expand its
strategic partnerships to benefit patients, caregivers, and healthcare
providers.
About Neurelis
Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system (CNS) market. Neurelis is leveraging its expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates to address significant unmet medical needs. The Neurelis technology platform includes Intravail®, ProTek® and Hydrogel™, three proprietary non-invasive drug delivery and stabilization technologies applicable to a wide-range of molecules including therapeutic proteins, peptides, non-peptide macromolecules and small molecules. For more information on Neurelis, please visit www.neurelis.com
